Wojtek Zbijewski

Wojtek Zbijewski is an Associate Professor at JHU Biomedical Engineering with over 15 years of experience in medical imaging technology, in particular in x-ray-based modalities – radiography, tomosynthesis, CT, micro-CT, and cone-beam CT. The research at his QuantIS lab uses advanced computer modeling and benchtop experiments to optimize imaging systems and algorithms for quantitative applications, focusing on orthopedics and pulmonology. His interests also include computational techniques to extract diagnostic information from image data, such as radiomics and shape analysis. The quantitative imaging technologies developed by Dr. Zbijewski are applicable to longitudinal evaluation of tissue engineering therapies in animal and human studies.

Youseph Yazdi

Dr Yazdi’s focus and expertise is on early-stage healthcare innovation.  He has over 30 years of experience in academia and industry in research, invention, product development, investment, and strategy all focused on medical devices.  Dr Yazdi received the BS degree in Electrical and Computer Engineering from Rice University, a MSE in Ultrasonics from UT-Austin, his PhD in Biophotonics from UT-Austin, and his MBA in Entrepreneurial Management from the Wharton School of Business at UPenn.  Most of his career has been in industry, at Johnson & Johnson, in R&D, Business Development, and as Corporate Director, Science & Technology. Dr Yazdi joined the faculty of Johns Hopkins School of Medicine in 2009 as head of the Johns Hopkins Center for Bioeng. Innovation & Design (CBID), and is also Associate Professor in the Department of Biomedical Engineering.

Rebecca Schulman

The Schulman group is developing molecular biosensor-based technologies for in situ sensing of the spatiotemporal dynamics of soluble proteins throughout a cell culture matrix or organoid. These technologies are designed to be multiplexed and appropriate for high-throughput screening.  The Schulman group also is developing molecular biosensors for measuring local mechanical modulus.

Her group also develops biomaterials for integrated sensing and spatiotemporally controlled protein release as well as mechanisms to modulate biomaterial mechanics and density in situ.  An overall technology goal is the development of systems for closed-loop feedback control of the biochemical and mechanical developmental niche.

Techniques: In vitro synthetic biology, biochemistry, imaging/longitudinal analysis, optimization/learning, hydrogel design and fabrication.

Vasiliki Machairaki

The focus of my work directly advances the Center’s core themes of personalized medicine, healthy aging, and disease modeling. By generating patient-specific hiPSC lines and modeling cellular vulnerability in AD, my research enables precision stratification of biologic subtypes and supports individualized therapeutic discovery. The generation of physiologically relevant 3D brain organoids together with highly controlled 2D in vitro models of distinct CNS cell types provide physiologically relevant platforms that capture early pathogenic processes, thereby contributing to innovative disease modeling strategies. Moreover, our emphasis on understanding cellular resilience, intercellular communication, and mechanisms of neurodegeneration aligns closely with the Center’s focus on promoting healthy aging through the identification of potential therapeutic targets and biomarkers.

Sangkyun Cho

My lab works at the intersection of stem cell biology, organoid engineering/bioprinting, and mechanobiology, with a particular focus on cardiovascular fibrosis and regenerative medicine. These efforts are well-aligned with TTREC’s foundational pillars in cell and tissue engineering and biomaterials, and they intersect with several of the Center’s cross-cutting themes, including disease modeling, healthy aging, and precision medicine. We are also deeply interested in leveraging proteomics and single-cell/spatial multi-omics to investigate the mechanisms by which stromal cells communicate dynamically with immune cells during disease and tissue repair, so I see many opportunities for synergistic collaboration in the immune engineering space as well.

1 2 3 6